1. Resource table {#s0005}
=================

Name of stem cell lineKCL029InstitutionKing\'s College London, London UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: <dusko.ilic@kcl.ac.uk>Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature (direct URL links and full references)1)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122--128.doi: 10.3109/14,653,249.2011.623692\
<http://www.ncbi.nlm.nih.gov/pubmed/22029654>\
2)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366--1381.doi: 10.1038/nprot.2012.080\
<http://www.ncbi.nlm.nih.gov/pubmed/22722371>Information in public databasesKCL029 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: 0225\
NIH Approval Number: NIHhESC-13-0225\
<http://grants.nih.gov/stem_cells/registry/current.htm?id=658>EthicsThe hESC line KCL029 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

2. Resource details {#s0010}
===================

Consent signedAug 12, 2009Embryo thawedAug 23, 2009UK Stem Cell Bank Deposit ApprovalDec 01, 2011\
Reference: SCSC11-46SexMale 46, XYGradeResearchDisease status\
([Fig. 1](#f0005){ref-type="fig"})c.814 T \> C mutation in the WAS gene and carrier for a mutation p.N1152H in the gene CFTRKaryotype (aCGH)Duplication of approximately 0.23 Mb from the long arm of chromosome 3; 3q29(197,574,292--197,803,820)× 3DNA fingerprint\
([Table 1](#t0005){ref-type="table"})Allele sizes (in bp) of 17 microsatellite markers specific for chromosomes 13, 18 and 21Viability testingPassPluripotent markers\
(immunostaining)\
([Fig. 2](#f0010){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityThree germ layers differentiation in vitro\
(immunostaining)\
([Fig. 3](#f0015){ref-type="fig"})Endoderm: AFP (α-fetoprotein)\
Ectoderm: TUBB3 (tubulin, β3 class III)\
Mesoderm: ACTA2 (actin, α2, smooth muscle)Sibling lines availableNo

We generated KCL029 clinical grade hESC line following protocols, established previously ([@bb0015], [@bb0020]). The expression of the pluripotency markers was tested after freeze/thaw cycle ([Fig. 2](#f0010){ref-type="fig"}). Differentiation potential into three germ layers was verified in vitro ([Fig. 3](#f0015){ref-type="fig"}).

3. Materials and methods {#s0015}
========================

3.1. Consenting process {#s0020}
-----------------------

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in the meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (PGD-V.8) were created on Jul. 01, 2010. HFEA Code of Practice that was in effect at the time of document creation: Edition 8 -- R.2 (<http://www.hfea.gov.uk/2999.html>). The donor couple signed the consent on Jan. 20, 2011. HFEA Code of Practice that was in effect at the time of donor signature: Edition 8 -- R.2. HFEA Code of Practice Edition 8 -- R.2 was in effect Apr. 07, 2010--Apr. 06, 2011.

3.2. Embryo culture and micromanipulation {#s0025}
-----------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details ([@bb0015], [@bb0020]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

3.3. Cell culture {#s0030}
-----------------

ICM plated on mitotically inactivated HFF were cultured as described ([@bb0015], [@bb0020]). TE cells were removed mechanically from outgrowth ([@bb0005], [@bb0010]). hESC colonies were expanded and cryopreserved at the third passage.

3.4. Viability test {#s0035}
-------------------

Straws with the earliest frozen passage (p.2--3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

3.5. Pluripotency markers {#s0040}
-------------------------

Pluripotency was assessed using two different techniques: enzymatic activity assay \[alkaline phosphatase (AP) assay\] and immunostaining as described ([@bb0015], [@bb0020]).

3.6. Differentiation {#s1040}
--------------------

Spontaneous differentiation into three germ layers was assessed in vitro and in vivo as described ([@bb1000], [@bb0015], [@bb0020]).

3.7. Genotyping {#s0045}
---------------

DNA was extracted from hESC cultures using a Chemagen DNA extraction robot according to the manufacturer\'s instructions. Amplification of polymorphic microsatellite markers was carried out as described ([@bb0015]). Allele sizes were recorded to give a unique fingerprint of each cell line.

3.8. Array comparative genomic hybridization (aCGH) {#s0050}
---------------------------------------------------

aCGH was performed as described in details ([@bb0015]).
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![Genetic pedigree tree. Both parents were carrying mutation in CFTR gene. Maternal CFTR mutation was p.N1152H and paternal ∆ F508 and exon 2 deletion. In addition, the mother carried c.814 T \> C mutation in WAS gene. The embryos were first genotyped for mutation in CFTR gene and then only normal and career embryos were assessed further for a mutation in WAS gene. Ab, abnormal; Af, affected; C, carrier; NA, non-applicable; ND, not determined.](gr1){#f0005}

![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress fibers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 100 μm.](gr2){#f0010}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (red) for mesoderm, β-III tubulin (red) for ectoderm and α-fetoprotein (red) for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 100 μm.](gr3){#f0015}

###### 

Genotyping. Microsatellite markers specific for chromosomes 13, 18, 21, X and Y were amplified. The allele sizes in bp for markers on chromosomes 13, 18, and 21 are listed in the table.

  Chr        Marker    Allele 1   Allele 2
  ---------- --------- ---------- ----------
  13         D13S252   294        298
  D13S305    447       455        
  D13S325    284       293        
  D13S628    457       457        
  D13S634    405       415        
  18         D18S386   352        375
  D18S390    360       372        
  D18S391    217       225        
  D18S535    482       482        
  D18S819    400       408        
  D18S976    476       480        
  D18S978    207       211        
  21         D21S11    248        248
  D21S1409   212       212        
  D21S1411   303       308        
  D21S1435   184       188        
  D21S1437   311       315        
